世界の市中感染メチシリン耐性黄色ブドウ球菌（CA-MRSA）治療薬市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A14407 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、87ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥522,000 (USD3,480)	▷ お問い合わせ
Multi User	￥783,000 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,044,000 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、市中感染メチシリン耐性黄色ブドウ球菌（CA-MRSA）治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。市中感染メチシリン耐性黄色ブドウ球菌（CA-MRSA）治療薬の種類別市場規模（VAL-301、GLPG-1492、ソリスロマイシン、塩酸アコラフロキサシン、その他）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市中感染メチシリン耐性黄色ブドウ球菌（CA-MRSA）治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Allergan Plc、Galapagos NV、Merck & Co Inc、Syntiron LLC、Valevia UK Ltd ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：VAL-301、GLPG-1492、ソリスロマイシン、塩酸アコラフロキサシン、その他 ・用途別分析2016年-2026年：病院、診療所、その他 ・市中感染メチシリン耐性黄色ブドウ球菌（CA-MRSA）治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・市中感染メチシリン耐性黄色ブドウ球菌（CA-MRSA）治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・市中感染メチシリン耐性黄色ブドウ球菌（CA-MRSA）治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・市中感染メチシリン耐性黄色ブドウ球菌（CA-MRSA）治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・市中感染メチシリン耐性黄色ブドウ球菌（CA-MRSA）治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug size is estimated to be xx million in 2021 from USD xx million in 2020, with a change of XX% between 2020 and 2021. The global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
VAL-301
GLPG-1492
Solithromycin
Acorafloxacin Hydrochloride
Others

Market segment by Application can be divided into
Hospital
Clinic
Others

The key market players for global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market are listed below:
Allergan Plc
Galapagos NV
Merck & Co Inc
Syntiron LLC
Valevia UK Ltd

Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug, with price, sales, revenue and global market share of Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug from 2019 to 2021.
Chapter 3, the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 VAL-301
1.2.3 GLPG-1492
1.2.4 Solithromycin
1.2.5 Acorafloxacin Hydrochloride
1.2.6 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size & Forecast
1.4.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales in Value (2016-2026))
1.4.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales in Volume (2016-2026)
1.4.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price by Type (2016-2026) & (USD/Pcs)
1.5 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production Capacity Analysis
1.5.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Total Production Capacity (2016-2026)
1.5.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Drivers
1.6.2 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Restraints
1.6.3 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Trends Analysis
2 Manufacturers Profiles
2.1 Allergan Plc
2.1.1 Allergan Plc Details
2.1.2 Allergan Plc Major Business
2.1.3 Allergan Plc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product and Services
2.1.4 Allergan Plc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Galapagos NV
2.2.1 Galapagos NV Details
2.2.2 Galapagos NV Major Business
2.2.3 Galapagos NV Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product and Services
2.2.4 Galapagos NV Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Merck & Co Inc
2.3.1 Merck & Co Inc Details
2.3.2 Merck & Co Inc Major Business
2.3.3 Merck & Co Inc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product and Services
2.3.4 Merck & Co Inc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Syntiron LLC
2.4.1 Syntiron LLC Details
2.4.2 Syntiron LLC Major Business
2.4.3 Syntiron LLC Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product and Services
2.4.4 Syntiron LLC Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Valevia UK Ltd
2.5.1 Valevia UK Ltd Details
2.5.2 Valevia UK Ltd Major Business
2.5.3 Valevia UK Ltd Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product and Services
2.5.4 Valevia UK Ltd Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Manufacturer
3.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturer Market Share
3.4.2 Top 6 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturer Market Share
3.5 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size by Region
4.1.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales in Volume by Region (2016-2026)
4.1.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region (2016-2026)
4.2 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2016-2026)
4.3 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2016-2026)
4.4 Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2016-2026)
4.5 South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2016-2026)
4.6 Middle East and Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales in Volume by Type (2016-2026)
5.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type (2016-2026)
5.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales in Volume by Application (2016-2026)
6.2 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application (2016-2026)
6.3 Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2016-2026)
7.2 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2016-2026)
7.3 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size by Country
7.3.1 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales in Volume by Country (2016-2026)
7.3.2 North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2016-2026)
8.2 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2016-2026)
8.3 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size by Country
8.3.1 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales in Volume by Country (2016-2026)
8.3.2 Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2016-2026)
9.2 Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2016-2026)
9.3 Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size by Region
9.3.1 Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2016-2026)
10.2 South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2016-2026)
10.3 South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size by Country
10.3.1 South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales in Volume by Country (2016-2026)
10.3.2 South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2016-2026)
11.2 Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2016-2026)
11.3 Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size by Country
11.3.1 Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Typical Distributors
12.3 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

List of Tables
Table 1. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type, (USD Million), 2021-2026
Table 2. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application, (USD Million), 2021-2026
Table 3. Allergan Plc Basic Information, Manufacturing Base and Competitors
Table 4. Allergan Plc Major Business
Table 5. Allergan Plc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product and Services
Table 6. Allergan Plc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Galapagos NV Basic Information, Manufacturing Base and Competitors
Table 8. Galapagos NV Major Business
Table 9. Galapagos NV Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product and Services
Table 10. Galapagos NV Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Merck & Co Inc Basic Information, Manufacturing Base and Competitors
Table 12. Merck & Co Inc Major Business
Table 13. Merck & Co Inc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product and Services
Table 14. Merck & Co Inc Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. Syntiron LLC Basic Information, Manufacturing Base and Competitors
Table 16. Syntiron LLC Major Business
Table 17. Syntiron LLC Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product and Services
Table 18. Syntiron LLC Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Valevia UK Ltd Basic Information, Manufacturing Base and Competitors
Table 20. Valevia UK Ltd Major Business
Table 21. Valevia UK Ltd Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Product and Services
Table 22. Valevia UK Ltd Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales (K Pcs), Price (USD/Pcs), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Manufacturer (2019-2021e) & (K Pcs)
Table 24. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 25. Market Position of Manufacturers in Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 26. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production Capacity by Company, (K Pcs): 2020 VS 2021
Table 27. Head Office and Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production Site of Key Manufacturer
Table 28. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug New Entrant and Capacity Expansion Plans
Table 29. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Mergers & Acquisitions in the Past Five Years
Table 30. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Region (2016-2021e) & (K Pcs)
Table 31. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Region (2021-2026) & (K Pcs)
Table 32. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region (2016-2021e) & (USD Million)
Table 33. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region (2021-2026) & (USD Million)
Table 34. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2016-2021e) & (K Pcs)
Table 35. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2021-2026) & (K Pcs)
Table 36. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type (2016-2021e) & (USD Million)
Table 37. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Type (2021-2026) & (USD Million)
Table 38. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price by Type (2016-2021e) & (USD/Pcs)
Table 39. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price by Type (2021-2026) & (USD/Pcs)
Table 40. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2016-2021e) & (K Pcs)
Table 41. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2021-2026) & (K Pcs)
Table 42. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application (2016-2021e) & (USD Million)
Table 43. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Application (2021-2026) & (USD Million)
Table 44. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price by Application (2016-2021e) & (USD/Pcs)
Table 45. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price by Application (2021-2026) & (USD/Pcs)
Table 46. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2016-2021e) & (K Pcs)
Table 47. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2021-2026) & (K Pcs)
Table 48. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2016-2021e) & (USD Million)
Table 49. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2021-2026) & (USD Million)
Table 50. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2016-2021e) & (K Pcs)
Table 51. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2021-2026) & (K Pcs)
Table 52. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2016-2021e) & (K Pcs)
Table 53. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2021-2026) & (K Pcs)
Table 54. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2016-2021e) & (K Pcs)
Table 55. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2021-2026) & (K Pcs)
Table 56. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2016-2021e) & (USD Million)
Table 57. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2021-2026) & (USD Million)
Table 58. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2016-2021e) & (K Pcs)
Table 59. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2021-2026) & (K Pcs)
Table 60. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2016-2021e) & (K Pcs)
Table 61. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2021-2026) & (K Pcs)
Table 62. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Region (2016-2021e) & (K Pcs)
Table 63. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Region (2021-2026) & (K Pcs)
Table 64. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region (2016-2021e) & (USD Million)
Table 65. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Region (2021-2026) & (USD Million)
Table 66. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2016-2021e) & (K Pcs)
Table 67. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2021-2026) & (K Pcs)
Table 68. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2016-2021e) & (K Pcs)
Table 69. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2021-2026) & (K Pcs)
Table 70. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2016-2021e) & (K Pcs)
Table 71. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2021-2026) & (K Pcs)
Table 72. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2016-2021e) & (USD Million)
Table 73. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2021-2026) & (USD Million)
Table 74. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2016-2021e) & (K Pcs)
Table 75. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2021-2026) & (K Pcs)
Table 76. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2016-2021e) & (K Pcs)
Table 77. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2021-2026) & (K Pcs)
Table 78. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2016-2021e) & (K Pcs)
Table 79. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Country (2021-2026) & (K Pcs)
Table 80. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2016-2021e) & (USD Million)
Table 81. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue by Country (2021-2026) & (USD Million)
Table 82. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2016-2021e) & (K Pcs)
Table 83. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Type (2021-2026) & (K Pcs)
Table 84. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2016-2021e) & (K Pcs)
Table 85. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales by Application (2021-2026) & (K Pcs)
Table 86. Direct Channel Pros & Cons
Table 87. Indirect Channel Pros & Cons
Table 88. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Typical Distributors
Table 89. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Typical Customers
List of Figures
Figure 1. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Picture
Figure 2. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type in 2020
Figure 3. VAL-301
Figure 4. GLPG-1492
Figure 5. Solithromycin
Figure 6. Acorafloxacin Hydrochloride
Figure 7. Others
Figure 8. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application in 2020
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Others
Figure 12. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size, (USD Million) & (K Pcs): 2020 VS 2021 VS 2026
Figure 13. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Size and Forecast (2016-2026) & (USD Million)
Figure 14. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales (2016-2026) & (K Pcs)
Figure 15. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 16. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production Capacity (2016-2026) & (K Pcs)
Figure 17. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Production Capacity by Geographic Region: 2020 VS 2021
Figure 18. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Drivers
Figure 19. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Restraints
Figure 20. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Trends
Figure 21. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Manufacturer in 2020
Figure 22. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Manufacturer in 2020
Figure 23. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 24. Top 3 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturer (Revenue) Market Share in 2020
Figure 25. Top 6 Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Manufacturer (Revenue) Market Share in 2020
Figure 26. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Region (2016-2026)
Figure 27. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Region (2016-2026)
Figure 28. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2016-2026) & (USD Million)
Figure 29. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2016-2026) & (USD Million)
Figure 30. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2016-2026) & (USD Million)
Figure 31. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2016-2026) & (USD Million)
Figure 32. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue (2016-2026) & (USD Million)
Figure 33. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2016-2026)
Figure 34. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Type (2016-2026)
Figure 35. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price by Type (2016-2026) & (USD/Pcs)
Figure 36. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2016-2026)
Figure 37. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Application (2016-2026)
Figure 38. Global Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Price by Application (2016-2026) & (USD/Pcs)
Figure 39. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2016-2026)
Figure 40. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2016-2026)
Figure 41. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country (2016-2026)
Figure 42. North America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Country (2016-2026)
Figure 43. United States Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Canada Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Mexico Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2016-2026)
Figure 47. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2016-2026)
Figure 48. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country (2016-2026)
Figure 49. Europe Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Country (2016-2026)
Figure 50. Germany Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. France Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. United Kingdom Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Russia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Italy Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Region (2016-2026)
Figure 56. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2016-2026)
Figure 57. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Region (2016-2026)
Figure 58. Asia-Pacific Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Region (2016-2026)
Figure 59. China Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Japan Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Korea Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. India Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Southeast Asia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Australia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2016-2026)
Figure 66. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2016-2026)
Figure 67. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country (2016-2026)
Figure 68. South America Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Type (2016-2026)
Figure 72. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Application (2016-2026)
Figure 73. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Sales Market Share by Country (2016-2026)
Figure 74. Middle East & Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue Market Share by Country (2016-2026)
Figure 75. Turkey Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Egypt Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Saudi Arabia Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. South Africa Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Drug Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source

---